A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks.

Abstract

The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine. Twenty-five patients completed a double-blind placebo-controlled multicrossover trial. The initial dose of ibuprofen was 1200 mg. Six migraine attacks were randomly treated in each patient, three with ibuprofen and three with placebo. The results indicated a statistically significant reduction in the duration of the migraine attacks and also a statistically significant reduction in the severity of headache and nausea in the ibuprofen-treated attacks. The use of additional medication was significantly reduced in the ibuprofen-treated attacks (25.6% vs 57.5%). No serious side effects were reported. Ibuprofen is valuable in the treatment of acute migraine attacks.

• Authors: R Kloster, K Nestvold, S T Vilming
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 12 Issue 3 Pg. 169-71; discussion 128 (Jun 1992) ISSN: 0333-1024 [Print] England
• PMID: 1623513 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Ibuprofen

Topics

• Acute Disease
• Adult
• Double-Blind Method
• Female
• Humans
• Ibuprofen (adverse effects, therapeutic use)
• Male
• Middle Aged
• Migraine Disorders (drug therapy)
• Time Factors